NEWS & VIEWS

Global private equity and venture capital news and research

Polaris Partners promotes Bitterman to partner after 10 years at firm

2 Apr 2014

Kevin Bitterman PolarisTechnology and healthcare-focused investment firm Polaris Partners has promoted Kevin Bitterman to partner after a decade at the firm.

Bitterman, who deals with healthcare investing for the firm, was co-founder of Sirtris Pharmaceuticals and Genocea Biosciences, which were sold to GlaxoSmithKline and listed on the Nasdaq stock exchange respectively.

Polaris managing partner Amir Nashat said, “For nearly a decade, Kevin has delivered incredible value to our partnership and our companies.

“His passion for science, entrepreneurial spirit, and pragmatic approach to company building has proven to be a tremendous asset for our portfolio.

“We are thrilled to recognize his commitment with this promotion and we look forward to his continued contributions now as a partner in the firm.”

Polaris was launched in 1996 and has more than $3.5bn of capital under management.

One of Polaris’ most recent investments was in genome editing specialist Editas Medicine as part of a $43m Series A round.

Flagship Ventures and Third Rock Ventures also took part in the financing for Editas, which attempts to use genome editing technology to treat the underlying cause of a broad range of diseases at the genetic level.

Copyright © 2014 AltAssets

FUNDRAISING & INVESTOR RELATIONS

Join the Private Equity & VC Fundraising & IR Group on LinkedIn. For LPs and GPs with an interest in private equity and venture capital fundraising, investor relations and marketing.

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014